Materiały źródłowe

• #1 Angelman syndrome – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/angelman-syndrome/diagnosis-treatment/drc-20355627

  There’s no cure for Angelman syndrome. Research is looking at targeting certain genes for treatment. Current treatment focuses on managing symptoms and addressing the developmental delays in children with Angelman syndrome. […] A team of healthcare professionals from different areas works with you to manage your child’s condition. Depending on your child’s symptoms, treatment for Angelman syndrome may involve: […] Anti-seizure medicine to control seizures. […] Physical or occupational therapy to help with walking and movement. […] Communication and speech therapy, which may include sign language and picture communication. […] Behavior therapy to help overcome hyperactivity and a short attention span and to aid in development. […] Medicines and sleep training to manage sleep issues. […] Diet changes and medicines to help with issues such as feeding troubles and constipation.

• #2 Angelman Syndrome: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/17978-angelman-syndrome

  Treatment options can help your child manage symptoms throughout their life. […] But treatment is available to help your child manage symptoms. This may include: Antiseizure medications, Communication aids and speech therapy, such as learning sign language, gesturing and using special communication devices, Early intervention and educational resources to help your child meet developmental milestones and reach academic goals, Physical therapy to help with balance, coordination and walking difficulties, Occupational therapy to help your child gain independence and perform everyday tasks, Using back, ankle or foot braces for support, Modified feeding methods for infants, like using special nipples, Following good sleep hygiene and setting a regular bedtime routine, Taking medications to help food move through your child’s gastrointestinal tract. […] Your child’s provider will recommend treatment options specific to your child’s symptoms and needs. Treatment is individualized for each person.

• #3 Angelman syndrome

  https://www.nhs.uk/conditions/angelman-syndrome/

  Your child may benefit from some of the following treatments and aids: […] anti-epileptic medicine to control seizures […] physiotherapy may improve posture, balance and walking ability; it’s also important to prevent permanent stiffening of the joints as people with Angelman syndrome get older […] communication therapy may help them develop non-verbal language skills, such as sign language and using visual aids, or ways to help them communicate such as Signalong, Makaton or PECS; using iPad applications and similar tablet devices may also help […] behavioural therapy may be recommended to help overcome behaviours you find hard to manage, such as hyperactivity and a short attention span. […] While there’s currently no cure for Angelman syndrome, research into treatments is being done in other countries. There are also clinical trials looking at treatment for some of the symptoms associated with Angelman syndrome, such as seizures.

• #4 Angelman syndrome – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/angelman-syndrome/symptoms-causes/syc-20355621

  People with Angelman syndrome tend to live close to a typical life span. But the condition can’t be cured. Treatment focuses on managing medical, sleep and developmental issues. […] Sleep troubles may improve with age. Medicine and behavior therapy may help.

• #5 Angelman Syndrome > Fact Sheets > Yale Medicine

  https://www.yalemedicine.org/conditions/angelman-syndrome

  Treatment includes physical therapy, speech therapy, occupational therapy, medication. […] While there is no cure for Angelman syndrome, treatments such as speech, physical, and occupational therapy, as well as anti-seizure medications, can help manage symptoms and improve quality of life. […] Treatment is tailored to each patient based on their symptoms and needs. Treatments may include: Anti-seizure medications (also known as anticonvulsants or anti-epileptic medications), which can help prevent, reduce, and lessen the severity of seizures. […] Physical and occupational therapy, which can help improve motor skills, such as walking, mobility, and balance. […] Speech therapy, which is used to manage speech problems. […] Behavioral therapy, which may help manage hyperactivity, sleep problems, aggressive or self-injurious behavior, and other behavioral concerns.

• #5 Angelman Syndrome > Fact Sheets > Yale Medicine

  https://www.yalemedicine.org/conditions/angelman-syndrome

  Good sleep habits and melatonin, which can help improve sleep problems. […] GERD treatments, which may include lifestyle modifications, medications, and, in some cases, surgery. […] Laxatives and/or a high-fiber diet, which may be used to treat constipation. […] Special nipples and feeding therapy, which may be used to improve feeding in babies with sucking problems. […] Central nervous system stimulants such as methylphenidate, which may be used to treat hyperactivity.

• #6 Angelman Syndrome – Child Neurology Foundation

  https://www.childneurologyfoundation.org/disorder/angelman-syndrome/

  There is no cure for AS at this time. However, supportive care can help children survive and reach their potential. Important therapies include: […] Patients with AS often have severe difficulty learning verbal language. They may be able to use modified forms of sign language for basic communication. […] Seizures can be difficult to control. Seizure control can be important for the survival of children with AS. This is because seizures can cause health complications. They can even rarely cause sudden death. Treatments include: Medication, Dietary therapy (such as a ketogenic diet), Neuromodulation (such as vagal nerve stimulation). […] AS cannot be cured, and children will not grow out of it. They will require lifelong assistance and care. […] People with AS can live as long as people without this syndrome. Some issues like sleep problems may improve with age.

• #7 ANGELMAN SYNDROME: CAUSES, SYMPTOMS, COMPLICATIONS, TREATMENT AND LATEST RESEARCH | Mya Care

  https://myacare.com/blog/angelman-syndrome-causes-symptoms-complications-treatment-and-latest-research

  Seizures occur in 80% of people with AS and typically require antiepileptic medications. Since seizures may change over time, regular monitoring by a neurologist is essential to adjust medications as needed. […] […] Managing hyperactivity, short attention span, and impulsivity in AS requires structured behavioral approaches: […] Applied Behavior Analysis (ABA): Reinforces positive behaviors and helps reduce self-injurious or disruptive actions. […] Sensory Integration Therapy: Addresses sensory-seeking behaviors (e.g., fascination with water, hand-flapping). […] Routine and Visual Schedules: Help reduce anxiety and improve predictability in daily activities. […] […] Sleep disturbances are common in AS, and strategies for better sleep include: […] Consistent bedtime routines.

• #7 ANGELMAN SYNDROME: CAUSES, SYMPTOMS, COMPLICATIONS, TREATMENT AND LATEST RESEARCH | Mya Care

  https://myacare.com/blog/angelman-syndrome-causes-symptoms-complications-treatment-and-latest-research

  Using white noise or weighted blankets for comfort. […] Melatonin supplements (under medical supervision). […] […] Individuals with AS often experience feeding difficulties and gastrointestinal (GI) issues such as reflux or constipation. Recommended strategies include: […] Soft, easy-to-chew foods for those with chewing/swallowing difficulties. […] High-fiber diets to prevent constipation. […] Specialized feeding therapy for infants with poor sucking reflexes. […] […] Lifelong regular checkups are necessary to manage associated health conditions: […] Orthopedic care for scoliosis or joint stiffness. […] Gastroenterology support for feeding and digestion issues. […] Vision and dental care to monitor for strabismus and teeth grinding. […] […] Through multidisciplinary care, people with AS can achieve better mobility, communication, and overall well-being. […]

• #8

  https://aesnet.org/abstractslisting/treatment-of-epilepsy-in-angelman-syndrome

  Angelman Syndrome (AS) is a genetic disorder which occurs in approximately 1 in 10,000 to 20,000 births. Epilepsy occurs in more than 80% of those with AS and is often intractable. We sought to examine a large cohort of patients with the goal of finding the most effective treatments for epilepsy in AS. Treatment of epilepsy among this population consisted of the use of anticonvulsant drugs (ACD) by all AS patients. Fifteen percent responded to the first medication used, whereas 78% were refractory to the first two medications and 64% had tried multiple medications (average of 3.2 medications). Of those who were refractory, 26% became seizure free with further treatment. At the time of data collection 40% were being treated with monotherapy (average current treatment of 1.2 medications). The most common of greater than 20 different medications tried were: valproate 62%, clonazepam 34%, phenobarbital 30%, topiramate 30%, lamotrigine 24%, carbamazepine 24%. For those who tried multiple medications the most effective were valproate, nitrazepam, levetiracetam, lamotrigine, clorazepate, topiramate, and clonazepam. Seventeen percent of respondents had also used non-pharmacologic treatments for epilepsy. These included dietary therapy with the classic ketogenic diet in 31/396 (8%) and the low glycemic index treatment in 7/396 (2%). Of those that tried the ketogenic diet, 36% felt it was the most effective treatment. The vagal nerve stimulator was used by 16/396 (4%) of the AS patients, and it proved the most effective treatment for 3 of the 16. Conclusions: Epilepsy occurs in over 80% of individuals with AS. Several of the new ACDs with broad spectrum efficacy were successful at providing seizure control and were well tolerated. Dietary therapy and the vagus nerve stimulator also appeared to significantly reduce seizures in individuals with AS.

• #9 Angelman’s Syndrome: Symptoms and Treatment | Doctor

  https://patient.info/doctor/angelmans-syndrome

  Suggested interventions include: […] Behavioural treatment may be a reasonable way to address sleep problems in some children with AS. […] Parents of children with AS have an increased risk of high levels of stress and mental health problems. These need to be addressed and managed appropriately. […] The most common preschool education programme used is 'Portage’. This provides particular help with language, socialisation, self-help skills and cognitive and motor skills in a step-wise fashion at home. […] It is common that a combination of treatment with anticonvulsants is needed to control seizures. […] Sodium valproate and clonazepam are the most effective medications and carbamazepine is one of the least effective. […] Sleep patterns may be helped by melatonin.

• #10 Angelman Syndrome: Pediatric Primary Care Guide – Topical Reviews in Pediatrics

  https://trip.utah.edu/angelman-syndrome-pediatric-primary-care-guide/

  Therapies Physical therapy, occupational therapy, and speech therapy with an emphasis on nonverbal methods of communication, including augmentative communication aids (e.g., picture cards or communication boards), signing, and electronic devices are beneficial. […] Most children with Angelman syndrome will require treatment for seizures; however, diagnosis can be challenging since movement abnormalities (e.g., non-epileptic myoclonus) can be mistaken for seizures, and EEG abnormalities can exist despite the absence of seizures. […] The most commonly used medications are levetiracetam and benzodiazepines (clonazepam, clobazam). The use of vigabatrin, carbamazepine, and tiagabine in children with Angelman syndrome may exacerbate certain types of seizures. […] When facing the complexities of Angelman syndrome, seeking guidance from specialists becomes paramount. Their expertise in various domains, such as gastroenterology, neurology, orthopedics, and sleep medicine, can provide insights and tailored recommendations for managing the unique challenges posed by Angelman syndrome.

• #10 Angelman Syndrome: Pediatric Primary Care Guide – Topical Reviews in Pediatrics

  https://trip.utah.edu/angelman-syndrome-pediatric-primary-care-guide/

  Many children will require long-term physical therapy if they are non-ambulatory or unstable in their gait. Children may also require positioning chairs and/or wheelchairs. Occupational therapy for fine motor problems and feeding difficulties may also be helpful. […] Strongly consider referral to Pediatric Neurology to discuss seizure types and prescribe rescue medication in the event an initial seizure is prolonged. […] Monitor antiepileptic medication levels and associated labs if necessary. Consultation with a Neurologist at one of the Angelman Syndrome Foundation clinics (Find a Clinic (ASF)) may be beneficial. […] Treatment for the pulmonary issues associated with Angelman syndrome should involve a multidisciplinary approach. […] Addressing sleep-related problems in Angelman syndrome involves establishing a consistent sleep-wake pattern and routine.

• #10 Angelman Syndrome: Pediatric Primary Care Guide – Topical Reviews in Pediatrics

  https://trip.utah.edu/angelman-syndrome-pediatric-primary-care-guide/

  No treatments are available for the underlying cause of Angelman syndrome. However, researchers are currently exploring gene therapy as well as strategies (such as antisense oligonucleotides) to reactivate the expression of the paternal UBE3A gene to allow it to express, mitigating the impact of the defective or missing maternal gene. […] Developmental therapy should begin at the time of diagnosis. This may be accessed through Early Intervention programs for children under 3. After age 3, developmental services may be available through the child’s school district or in private settings, depending on resources. […] Most children with Angelman syndrome will use only nonverbal methods of communication. Attempts to teach signing should begin as soon as the child is sufficiently attentive. Speech therapy should be initiated promptly, focusing on nonverbal methods of communication such as signing, gestures, picture cards, communication boards, and electronic alternative communication devices.

• #10 Angelman Syndrome: Pediatric Primary Care Guide – Topical Reviews in Pediatrics

  https://trip.utah.edu/angelman-syndrome-pediatric-primary-care-guide/

  Management strategies may include medications to reduce saliva production or referral to an ENT specialist for botulinum toxin injections to address excessive drooling effectively. […] The treatment plan often includes behavior management and medications when behavioral management alone is ineffective. Stimulants such as methylphenidate can help with hyperactivity. For self-injurious behavior or aggressive behaviors, or hyperactivity not helped by stimulant medication, atypical antipsychotics may be useful. […] There is currently no approved therapy specific to Angelman syndrome. One of the main therapeutic strategies currently being explored for Angelman syndrome involves reactivating the expression of the paternal UBE3A allele in the CNS (9, 10) using Antisense Oligonucleotides administered intrathecally (ASO therapy).

• #11 Treatments for Angelman Syndrome | Angelman Syndrome NewsEnvelope icon

  https://angelmansyndromenews.com/treatments-for-angelman-syndrome/

  Angelman syndrome (AS) is a genetic disorder that delays development and causes neurological problems and seizures. Currently, there is no cure for AS, and available treatments focus on controlling seizures and managing the physical and behavioral symptoms of the disease. […] Common medication used to manage seizures include Depacon (sodium valproate), Klonopin (clonazepam), lamotrigine, Luminal (phenobarbital), Topamax (topiramate), and Keppra (levetiracetam). […] Physiotherapy can identify problem areas and introduce a tailored exercise plan that can, for example, improve motor skills, strength, posture, and balance. […] An occupational or physical therapist can identify whether braces are needed, and help to order and to fit them. […] Speech and language therapists should be involved from an early stage to assess speech development in the child and help identify what approaches will benefit them the most.

• #11 Treatments for Angelman Syndrome | Angelman Syndrome NewsEnvelope icon

  https://angelmansyndromenews.com/treatments-for-angelman-syndrome/

  Behavioral therapy may be able to help address and cope with these issues. […] Medication such as Risperdal (risperidone) may be used to manage hyperactive and socially-disruptive behavior, but this should not be used as a long-term solution. […] This can be treated by maintaining an upright position during and after eating, or with medication such as Gaviscon and ranitidine.

• #12 Angelman syndrome in Poland: current diagnosis and therapy status—the caregiver perspective: a questionnaire study | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03292-w

  The timing of early initiation of speech therapy and rehabilitation seems to be particularly important. […] Early diagnosis of AS is crucial for improving the prognosis and achieving satisfactory treatment outcomes for patients. […] It is important that a correct diagnosis of AS is not preceded by another diagnosis. […] Although the majority of the patients in the study group were treated with the recommended medications, 8.6% have been reported to be treated using vigabatrin, which is not recommended in AS. […] Sleep disorders are one of the most troublesome symptoms present in the course of AS, posing a problem for the whole family living with the patient. […] According to recommendations, every patient diagnosed with AS should be under the supervision of a gastroenterologist. […] A low-carbohydrate diet is used in 12.9% of patients, including a ketogenic diet in 7.1% of individuals, most commonly in patients with deletion.

• #12 Angelman syndrome in Poland: current diagnosis and therapy status—the caregiver perspective: a questionnaire study | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03292-w

  Angelman syndrome (AS) is a rare neurodevelopmental disease caused by imprinting disorders that impede the production of the ubiquitin E3A ligase protein (UBE3A). […] A ketogenic diet was used in 7.1% of patients. […] The care of patients with AS in Poland is carried out according to the European and world standards, however there is an impeded access to clinical geneticist, and the knowledge about rare diseases among primary healthcare physicians could be improved. […] There is a need for creation a specialized centers and databases for AS patients. […] The basic characteristics of AS should be more widely disseminated among pediatricians and other health care professionals in order to improve standards regarding the diagnosis and treatment process, as well as the quality of life of patients and their families.

• #12 Angelman syndrome in Poland: current diagnosis and therapy status—the caregiver perspective: a questionnaire study | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03292-w

  The next direction should be the search for new physiotherapeutic methods that will be very specifically tailored to reducing AS symptoms. […] The most commonly used form of therapy is AAC alongside work with a speech therapist. […] The occurrence of a rare disease in a family often experience negative impact on the psychological well-being of its individual members. […] The biggest difficulties reported by caregivers are finding an appropriate specialist and the lack of sufficient knowledge about rare diseases among healthcare professionals in Poland.

• #13 Managing Angelman Syndrome with Care | Rising Above ABA

  https://www.risingaboveaba.com/autism-blog/angelman-syndrome

  Some individuals with Angelman syndrome may benefit from specific dietary interventions, such as the ketogenic diet or modified Atkins diet, which have shown promise in reducing seizure frequency and improving overall cognitive function. […] Physical, occupational, and speech therapies play a crucial role in managing Angelman syndrome. These therapies focus on improving motor skills, enhancing communication abilities, and promoting overall physical and cognitive development. […] Applied behavior analysis and behavior therapy may be beneficial in addressing behavioral concerns, such as hyperactivity, aggression, self-injury, and repetitive behaviors. These therapies help individuals develop coping strategies and learn appropriate social and communication skills. […] Participation in clinical trials and research studies is of great importance in expanding knowledge and advancing the understanding, detection, treatment, and prevention of Angelman syndrome. Researchers and clinicians rely on the involvement of individuals with Angelman syndrome and their families to gather valuable data and insights. By participating in these studies, volunteers contribute to the development of novel therapies and interventions.

• #13 Managing Angelman Syndrome with Care | Rising Above ABA

  https://www.risingaboveaba.com/autism-blog/angelman-syndrome

  When it comes to managing Angelman syndrome, a comprehensive approach that addresses the diverse symptoms and challenges associated with the condition is essential. While there is no specific therapy for Angelman syndrome, treatment focuses on improving quality of life and addressing specific symptoms that individuals may experience. This section will explore therapeutic approaches and the importance of clinical trials and research studies in advancing the understanding and treatment of Angelman syndrome. […] Therapeutic approaches for Angelman syndrome aim to address various aspects of the condition, such as reducing seizures, anxiety, gastrointestinal issues, and improving sleep. Treatment strategies may include: […] Medications can be prescribed to manage seizures, alleviate anxiety, and improve sleep. Each individual’s medication regimen is tailored to their specific needs and may involve anticonvulsant drugs, anti-anxiety medications, and sleep aids.

• #14 Treatment Opportunities Seen for Angelman Syndrome | NIH Record

  https://nihrecord.nih.gov/2020/04/17/treatment-opportunities-seen-angelman-syndrome

  One promising new therapeutic for Angelman seizures is cannabidiol (CBD), the non-psychoactive substance Philpot jokingly referred to as a hippies disappointment. […] Using synthetic CBD, which is about 99 percent pure, Philpots group has shown reduced seizure duration and severity in AS mice. […] A much more transformative treatment would be to treat the disorder at its genetic core, Philpot said, explaining his groups efforts to reactivate the silent UBE3A gene. […] We were able to show that a drug, Topotecan, can very powerfully turn on the paternal allele of UBE3A, he said. […] Researchers have identified other small molecule compounds that they can deliver peripherallyand less invasivelybut with similar gene-reactivating effects on AS mice. […] Philpot also emphasized the need to develop acceptable measurementsbiomarkersfor use in human clinical trials. […] The dream is were going to treat [AS] with a small molecule or some other type of therapy that could come in like a flurry of snowflakes and reactivate this dormant allele and make the neurons happy and healthy and pink and try to help these individuals with Angelman syndrome, he concluded.

• #14 Treatment Opportunities Seen for Angelman Syndrome | NIH Record

  https://nihrecord.nih.gov/2020/04/17/treatment-opportunities-seen-angelman-syndrome

  They may have the cheerful faces and demeanor of cherubs, but people with Angelman syndrome (AS), a rare neurodevelopmental disorder, also face significant lifelong challenges, including seizures, problems with balance and movement, and an inability to speak. […] We want to help these individuals who are so wonderful yet so challenged in life, and to help their caregivers. […] Currently, scientists are developing three strategies to treat the disorderrelieve symptoms, reactivate the dormant UBE3A or apply traditional gene therapy. […] In efforts to relieve a major symptomseizures, for exampledoctors use anti-epileptic medications, nutritional interventions such as ketogenic or low-glycemic-index diets, and, in rare circumstances, surgery. […] Even with all of these anti-epileptics at our disposal, he noted, many of these individuals are refractory to the traditional anti-epileptics, so we need yet another line of treatment for seizures in individuals with Angelman syndrome.

• #15 Angelman Syndrome | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/angelman-syndrome

  Treatment focuses on the behaviors associated with the disorder […] Treatment for Angelman syndrome focuses on managing the child’s medical problems and developmental delays since there is no cure to repair chromosomes. Treatment may include the following: […] Physical therapy to help with joint mobility and movement […] Speech therapy […] Occupational therapy […] Behavior therapy.

• #16 A Comprehensive Approach to Rehabilitation Interventions in Patients with Angelman Syndrome: A Systematic Review of the Literature

  https://www.mdpi.com/2035-8377/13/3/36

  Because AS is a multisystem disorder, patients with AS require multidisciplinary interventions throughout their lives. […] What emerged from this systematic review is that different rehabilitation approaches can be used according to motor, functional, and communicative problems. A full range of educational training and enrichment programs should be available. Unstable or no ambulatory children may benefit from physical therapy, which can improve balance and movements if started early and protracted over time. Occupational therapy may help support personal autonomy, above all in toileting and incontinence. Speech therapy is essential and should focus on nonverbal methods of communication. Augmentative communication aids such as picture cards, ENGs, or communications boards should be used at the earliest appropriate time in order to encourage social interaction and avoid exclusion. […] Even if all studies included in this review demonstrated that rehabilitation in AS patients is necessary to improve their quality of life and autonomy, caution should be adopted in the interpretation of our findings.

• #17 What is Angelman Syndrome? – NAPAAccessibility ToolsIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontResetNAPA 澳大利亚普通话信息

  https://napacentre.com.au/angelman-syndrome-therapy/

  Early intervention should begin as soon as a diagnosis of Angelman syndrome has been made, as it can result in significant improvements in gross motor, fine motor, and communication skills. […] Physiotherapy may focus on improving mobility, muscular strength, coordination, and endurance. […] Occupational therapy may target improving upper limb strength, upper extremity function, and posture to support activities of daily living, such as dressing. […] Speech and language pathology may support with increasing speech intelligibility (i.e., ability to be understood) as well as developing expressive and receptive language.

• #18 Angelman syndrome in children – Children’s Health Neurology

  https://www.childrens.com/specialties-services/conditions/angelman-syndrome

  Children’s Health has the expertise and resources to help your child with any issue they may experience with Angelman syndrome. […] Nutritionists can help your child if they are experiencing seizures that can’t be controlled with medication. If your child is experiencing seizures and anti-seizure medication isn’t working, a high-fat, low-carbohydrate diet (ketogenic diet) might help. You and your child will work with one of our nutritionists to learn more about this diet. […] Physical therapists (PT) helps your child improve their muscle tone and walking gait. […] Physical medicine and rehabilitation specialists and a mobility clinic providers will create customized orthotics or braces to help keep your child’s feet straight. Your child might also need an active stroller or wheelchair for longer distances because a crouched gait can make walking difficult. […] Sleep specialists will help your child if they have severe sleep problems. […] Speech-language therapists will help your child better express themselves if they have limited speech. Sign language, visual aids or speech technology aids can be helpful.

• #19 Angelman syndrome (AS): Definition, causes, and treatments

  https://www.medicalnewstoday.com/articles/angelman-syndrome-as

  There is currently no cure for AS. However, researchers believe there is a high possibility of discovering an effective treatment, according to the Angelman Syndrome Foundation. […] Currently, early treatment can help manage symptoms. The options include: anti-seizure medication, behavioral therapy and sleep routines to help manage sleeping problems, breastfeeding support, such as special nipples, to help babies suckle, upright positioning for feeding and medicines to help digestion, physical therapy, ankle braces or supports to help walking, braces or corrective surgery for severe scoliosis, social support, speech and occupational therapy, picture-based or computer technology to help with communication. […] A range of treatments can help manage symptoms. These may include medications, physical therapy, and speech and occupational therapies.

• #20 Gene therapy shows promise for Angelman syndrome treatment

  https://www.drugtargetreview.com/news/98931/gene-therapy-shows-promise-for-angelman-syndrome-treatment/

  A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition. […] There is currently no specific treatment, however, the team, led by Professor Ben Philpot, previously suggested that the best way to treat the disorder would be to restore function of the UBE3A gene in neurons, which has been lost in the brains of people with Angelman syndrome. […] This treatment restored motor skill-learning and the essential mouse behaviours of digging, burrowing and nest-building and they did not become as susceptible as their untreated counterparts to experimentally induced epileptic seizures. […] The researchers plan to further develop their strategy and ultimately enter the therapy into human clinical trials. If such a therapy were available, it could deliver benefits to individuals of any age with varying benefits. The range from birth to four years is probably ideal, but we think that whenever we can reinstate this genes function in the brain, we are likely to see some improvements, Philpot concluded.

• #21 Angelman Syndrome | Genetic Disorder | ForPatients by Roche

  https://forpatients.roche.com/en/trials/neurodevelopmental-disorder/angelman-syndrome.html

  There are currently no disease-modifying treatments for Angelman syndrome. The management of AS is mostly symptomatic, meaning that slowing or lessening the symptoms of AS is the main goal, such as controlling seizures. […] Children with AS tend to have limited speaking skills, so speech and language therapy with the use of picture cards, sign language or applications on a phone or tablet can improve their non-verbal skills. […] Other options try to manage the additional symptoms of AS. Modification of the diet or medicines can help with constipation and reflux disease. It is common practice to prescribe drugs to help with sleeping issues. Breastfeeding might not be possible, and using special nipples, monitoring weight gain and visiting a specialised team to help with breastfeeding problems is advised. For the developmental delay, early and individualised intervention programs can be organised. Physiotherapy may improve walking ability and balance. Behavioural therapy may help with overcoming hyperactivity or short attention span.

• #22 Symptoms, Causes, and Treatments of Angelman Syndrome

  https://www.verywellhealth.com/angelman-syndrome-overview-4171630

  Speech and language therapy may help insofar as it stresses word recognition and may enhance the quality of verbal and non-verbal interactions. […] GERD can often be controlled with diet, antacids, and proton pump inhibitors (PPIs). […] Investigational research is underway to see if certain pharmaceutical agents can activate nerve receptors believed to be behind Angelman syndrome and other forms of genetically induced intellectual disabilities.

• #23 Unmet clinical needs and burden in Angelman syndrome: a review of the literature | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-017-0716-z

  There are very few studies examining efficacy of specific treatments for movement disorders in AS, and most of the studies that have been done have been case reports. […] Standard of care for movement disorders typically involves assessment and intervention by physical therapists and occupational therapists. […] One nonplacebo, single-arm trial of minocycline found an improvement in auditory comprehension (but not expressive communication) in children ages 4 to 12 years diagnosed with AS. […] Although some medications have been suggested as possibly being helpful to treat specific behavioral issues (e.g., stimulants for hyperactivity, antipsychotics for aggression), no evidence-based studies have indicated the efficacy of these treatments in AS. […] Individuals with AS may have significantly low levels of melatonin with a delayed melatonin peak, which may explain why melatonin has been a successful treatment option for some individuals. […] Although melatonin is a promising treatment, it is not considered standard of care for everyone, primarily because it is ineffective for some individuals.

• #24 Angelman syndrome | Description, Cause, Symptoms, & Treatment | Britannica

  https://www.britannica.com/science/Angelman-syndrome

  The symptoms and characteristics of Angelman syndrome are similar to those of autism, Prader-Willi syndrome, and cerebral palsy, which can lead to misdiagnosis and delayed treatment and care. Thus, genetic testing is needed to provide a definitive diagnosis of Angelman syndrome. […] There is no cure for Angelman syndrome. However, many of its symptoms can be managed, and some symptoms may become less severe over time. Examples of symptom management include the use of a high-calorie formula for infants with feeding difficulties and the use of medication and dietary therapies for seizures. Sleep problems, which often lessen with age, can be treated with medications and sleep training. Hyperactivity often also decreases with age. Physical, occupational, and speech therapies can help improve motor and speech skills, and some individuals may learn to communicate nonverbally or by using specialized devices.

• #25 Angelman syndrome – Wikipedia

  https://en.wikipedia.org/wiki/Angelman_syndrome

  No cure is available. Treatment is generally supportive in nature. Anti-seizure medications are used in those with seizures. Physical therapy and bracing may help with walking. […] There is currently no approved cure available. The epilepsy can be controlled by the use of one or more types of anticonvulsant medications. However, there are difficulties in ascertaining the levels and types of anticonvulsant medications needed to establish control, because people with AS often have multiple types of seizures. Many families use melatonin to promote sleep in a condition which often affects sleep patterns. Mild laxatives are also used frequently to encourage regular bowel movements. Additionally, among a cohort of 163 individuals with AS, ranitidine was shown to be the most frequently prescribed medication for treating gastroesophageal reflux disease (GERD). Early intervention with physiotherapy is sometimes used to encourage joint mobility and prevent stiffening of the joints.

• #25 Angelman syndrome – Wikipedia

  https://en.wikipedia.org/wiki/Angelman_syndrome

  Occupational therapists can contribute to the development and augmentation of non-verbal communication skills by addressing the foundational skills such as finger isolation, motor planning, hand-eye coordination, spatial awareness, and refining gestures. This is important because individuals with Angelman Syndrome who already possess some form of non-verbal communication have a much harder time adapting to changes in a new or existing AAC device because they can communicate their needs much faster nonverbally. […] An experimental treatment, currently in clinical development by Roche, targets the GABAA 5 receptor. Alogabat is a small molecule that acts as a positive allosteric modulator (PAMs) of the receptor. It does not involve replacing or activating the UBE3A gene, instead it is a mechanism aimed at improving various symptoms of AS such as learning, sleep, and seizure control.

• #26 Paramedical Services for Children With Angelman SyndromeEnvelope icon

  https://angelmansyndromenews.com/health-insights/paramedical-services-for-angelman-syndrome/

  A dietician may also propose a special diet to help with seizures, which are very common in children with Angelman syndrome. […] A behavioral therapist can work with your child to help change such behavior. They can also help you with learning how to determine the likely cause of these behaviors, such as boredom, frustration, or pain, so that you might better prevent or minimize them.

• #26 Paramedical Services for Children With Angelman SyndromeEnvelope icon

  https://angelmansyndromenews.com/health-insights/paramedical-services-for-angelman-syndrome/

  Paramedical services are of paramount importance for patients with chronic and complex neurological disorders like Angelman syndrome. […] Here is information about paramedical services and its various fields, some of which can help in managing disease symptoms and improving patients’ quality of life. […] Occupational therapy can help your child with daily life skills affected by the disease: motor function, visual perception, and sensory awareness. Therapists can also work with your child to help them with self-care activities that may allow them a greater degree of independence. […] Physiotherapy can provide safe exercises to help them develop the strength and muscle control necessary for these skills, and improve their mobility. […] Speech therapy can help teach your child how to communicate their needs better, including in ways that do not require a verbal exchange.

• #27 Researchers identify potential treatment for Angelman syndrome | UNC-Chapel Hill

  https://www.unc.edu/posts/2024/07/15/researchers-identify-potential-treatment-for-angelman-syndrome/

  A small molecule could lead to effective therapy for the rare genetic disorder, UNC School of Medicine scientists say. […] Though there isnt a cure for the condition, new research at the UNC School of Medicine is setting the stage for one. […] A kind of gene therapy, this potential treatment could lead to proper protein and cell function for individuals with Angelman syndrome. […] This small molecule provides an excellent starting point for developing a safe and effective treatment for Angelman syndrome. […] No other small molecule compound has yet to show such promise for Angelman, he added. […] One compound, (S)-PHA533533, shows promise, but researchers are still working to identify the precise target inside cells that causes the desired effects of the drug. […] However, this gives us a compound that we can work with to create an even better compound that could be moved forward to the clinic.

• #28 Angelman Therapeutics – Angelman Syndrome Foundation

  https://www.angelman.org/for-parents/angelman-therapies/

  It’s an exciting time! There is a lot going on in the world of therapeutics for Angelman syndrome. Below, find descriptions of the different therapeutic approaches that are being developed as treatments and a possible cure for Angelman Syndrome. […] There are four broad strategies for therapies—gene therapy, reactivation, pathway intervention and symptomatic treatment. Below, you will find an explanation of each type, how the therapeutic is administered and some pros and cons. […] Gene therapy is the process of delivering the missing gene — UBE3A, directly to the appropriate cell type using an engineered virus. […] Reactivation approaches are finding ways to turn on the father’s copy of UBE3A. […] Reactivation using Topoisomerase inhibitors ASF Funded Research by Ben Philpot (UNC) first showed that it is possible to turn on the paternal copy of Ube3a in mice using topoisomerase inhibitors.

• #29 Gene Therapy Shows Early Promise as Angelman Syndrome Treatment | Newsroom

  https://news.unchealthcare.org/2021/10/gene-therapy-shows-early-promise-as-angelman-syndrome-treatment/

  Led by Ben Philpot, PhD, and Matt Judson, PhD, the new therapy was generally well-tolerated and prevented key signs of the condition in animal models. […] Scientists at the UNC School of Medicine have reported in the journal JCI Insight encouraging early tests of a gene therapy strategy against Angelman syndrome, a neurodevelopmental disorder that features poor muscle control and balance, hard-to-treat epilepsy, and intellectual disabilities. […] There is no specific treatment, but scientists led by Ben Philpot, PhD, previously suggested that the best way to treat the disorder would be to restore function of the UBE3A gene in neurons, which has been lost in the brains of people with Angelman syndrome. […] Philpot and colleagues verified that vector-borne UBE3A became active in neurons throughout the Angelman model mouse brain just days after injection, at a level similar to that of the normal gene. This treatment restored motor skill-learning and the essential mouse behaviors of digging, burrowing, and nest-building.

• #29 Gene Therapy Shows Early Promise as Angelman Syndrome Treatment | Newsroom

  https://news.unchealthcare.org/2021/10/gene-therapy-shows-early-promise-as-angelman-syndrome-treatment/

  This was a proof-of-concept study, but if these early results were translated to the clinic, they would represent big improvements in the quality of life for individuals with Angelman syndrome, said study lead author Matt Judson, PhD. […] The researchers plan to further develop their strategy, first with more tests in mice and monkeys to optimize dose and delivery methods, and ultimately, pending promising safety results, human clinical trials. […] If such a therapy were available, the researchers expect it might be able to deliver benefits to individuals of any age, but perhaps with varying benefits. […] The range from birth to four years is probably ideal, but we think that whenever we can reinstate this gene’s function in the brain, we’re likely to see some improvements, Philpot said.

• #30 Potential therapeutic approaches for Angelman syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4902328/

  Since the majority of AS cases are caused by UBE3A deficiency, several groups have attempted to restore UBE3A expression by direct gene therapy or by un-silencing the paternal allele. Injection of recombinant adeno-associated virus (AAV) carrying the mouse Ube3a into the hippocampus of AS mice restored local Ube3a expression and improved hippocampus-dependent learning and memory. However, the viral vectors showed limited distribution beyond the hippocampus and there was no effect on motor dysfunction. […] Several lines of evidence have indicated that paternal UBE3A silencing in both neurons and induced Pluripotent Stem Cells (iPSC) from AS patients is due to the expression of a long non-coding antisense RNA, UBE3A-ATS. Recent research with AS mice has shown that Ube3a-ATS is an atypical RNAPII transcript, which functions to suppress paternal Ube3a expression. Therefore, suppression of UBE3A-ATS expression becomes an attractive approach to reactivate the paternal allele.

• #30 Potential therapeutic approaches for Angelman syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4902328/

  The fact that genetic truncation of UBE3A-ATS more effectively rescues phenotypic defects than ASOs treatment in AS mice has two therapeutic implications: i) long-lasting unsilencing is required; and ii) early, prenatal, UBE3A expression is critical. […] In parallel to attempts at increasing UBE3A expression, several groups have explored alternative approaches to rescue synaptic plasticity and cognitive functions. These alternative approaches are based on findings related to the molecular underpinnings of abnormal synaptic plasticity in AS mice and to evidence that autism-related monogenetic syndromes share alterations in a common set of synaptic mechanisms. […] Rapamycin treatment of AS mice normalized imbalanced mTORC1 and mTORC2 signaling in the cerebellum and significantly improved cerebellum-dependent motor learning. Collectively, the current literature seems to suggest that the mTOR signaling pathway is the converging point in several neurodevelopmental disorders, especially autism-related diseases. However, whether rapamycin or its analogs have any beneficial effects in AS or other autism-related diseases awaits further preclinical research and clinical trials.

• #30 Potential therapeutic approaches for Angelman syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4902328/

  Angelman syndrome (AS) is a neurodevelopmental disorder caused by deficiency of maternally inherited UBE3A, an ubiquitin E3 ligase. Despite recent progress in understanding the mechanism underlying UBE3A imprinting, there is no effective treatment. Further investigation of the roles played by UBE3A in the central nervous system (CNS) is needed for developing effective therapies. […] Advances in understanding UBE3A imprinting provide a unique opportunity to induce paternal UBE3A expression, thus targeting the syndrome at its root. However, such efforts have yielded less-than-expected rescue effects in AS mouse models, raising the concern that activation of paternal UBE3A after a critical period cannot correct all the CNS defects that developed in a UBE3A-deficient environment. On the other hand, targeting abnormal downstream cell signaling pathways has provided promising rescue effects in preclinical research. Thus, combined reinstatement of paternal UBE3A expression with targeting abnormal signaling pathways should provide better therapeutic effects.

• #31 Gene therapy shows early promise as Angelman syndrome treatment | Braceworks Custom Orthotics

  https://braceworks.ca/2022/03/18/health-tech/gene-therapy-shows-early-promise-as-angelman-syndrome-treatment/

  This was a proof-of-concept study, but if these early results were translated to the clinic, they would represent big improvements in the quality of life for individuals with Angelman syndrome. […] The researchers plan to further develop their strategy, first with more tests in mice and monkeys to optimize dose and delivery methods, and ultimately, pending promising safety results, human clinical trials. […] If such a therapy were available, the researchers expect it might be able to deliver benefits to individuals of any age, but perhaps with varying benefits. […] The range from birth to four years is probably ideal, but we think that whenever we can reinstate this gene’s function in the brain, we’re likely to see some improvements.

• #32 Towards a therapy for Angelman syndrome by targeting a long non-coding RNA | Nature

  https://www.nature.com/articles/nature13975

  Angelman syndrome is a single-gene disorder characterized by intellectual disability, developmental delay, behavioural uniqueness, speech impairment, seizures and ataxia. […] Despite a clear understanding of the disease-causing event in Angelman syndrome and the potential to harness the intact paternal allele to correct the disease, no gene-specific treatment exists for patients. Here we developed a potential therapeutic intervention for Angelman syndrome by reducing Ube3a-ATS with antisense oligonucleotides (ASOs). ASO treatment achieved specific reduction of Ube3a-ATS and sustained unsilencing of paternal Ube3a in neurons in vitro and in vivo. Partial restoration of UBE3A protein in an Angelman syndrome mouse model ameliorated some cognitive deficits associated with the disease. […] Frank Rigo and colleagues report the development of the first gene-specific therapy for Angelman syndrome, a severe neurodevelopmental disorder caused by disrupted function of the maternal copy of the imprinted gene UBE3A. The paternal copy of UBE3A is intact but silenced by a long non-coding RNA antisense transcript, UBE3A-ATS. The authors show that by reducing Ube3a-ATS with antisense oligonucleotides (ASOs), the silencing of paternal Ube3a can be reversed in cultured mouse neurons and in vivo. Some phenotypes in an Angelman syndrome mouse model, including obesity and memory impairment can also be corrected.

• #33 Angelman Syndrome: How late is too late for treatment? | eLife

  https://elifesciences.org/articles/86117

  Experiments on mice suggest that an approach called antisense oligonucleotide therapy may be able to treat some symptoms of Angelman syndrome, including problems with epilepsy and sleep. […] Using ASO therapy to interfere with the antisense transcript and thus allowing the intact copy of UBE3A to be expressed is a promising approach for the treatment of Angelman syndrome. […] The findings of Lee et al. illustrate that it may be possible to treat some aspects of Angelman syndrome after birth, and even into adulthood, using ASO therapeutics. This challenges the current view of what symptoms of Angelman syndrome are treatable, and at what age. […] Here, we report that reducing Ube3a-ATS by antisense oligonucleotides in juvenile or adult maternal Ube3a knockout mice rescues the abnormal electroencephalogram (EEG) rhythms and sleep disturbance, two prominent clinical features of Angelman syndrome. Importantly, the degree of phenotypic improvement correlates with the increase of Ube3a protein levels. These results indicate that the therapeutic window of genetic therapies for Angelman syndrome is broader than previously thought, and EEG power spectrum and sleep architecture should be used to evaluate the clinical efficacy of therapies.

• #34 News: A Single Cas9 Injection Could Mean a Lifetime of Treatment for Angelman Syndrome – CRISPR Medicine

  https://crisprmedicinenews.com/news/a-single-cas9-injection-could-mean-a-lifetime-of-treatment-for-angelman-syndrome/

  A CRISPR-Cas9 treatment reactivated a crucial gene in mice and human neurons hinting at a possible one-time treatment for Angelman syndrome. […] In a new first, scientists have developed what could become a one-time Cas9 treatment for Angelman syndrome that would replace frequent, invasive injections. […] But now, about 20 years since scientists first realized it’s possible to treat Angelman syndrome at all, research in the journal Nature shows that the disease could be at least mostly reversed at or around birth. […] A small handful of early-stage clinical trials, including those launched by the Foundation for Angelman Syndrome Therapeutics (FAST) are investigating the use of antisense oligonucleotides to reawaken the paternal UBE3A gene. […] An oligonucleotide treatment, which was first demonstrated in Arthur Beaudet’s lab, could make a huge difference for Angelman families if the clinical trials go well.

• #34 News: A Single Cas9 Injection Could Mean a Lifetime of Treatment for Angelman Syndrome – CRISPR Medicine

  https://crisprmedicinenews.com/news/a-single-cas9-injection-could-mean-a-lifetime-of-treatment-for-angelman-syndrome/

  If you can replicate what the [oligonucleotides] do in a therapy that can be injected only once that’s going to reduce the cost, that’s going to reduce the complexity for that individual over their lifespan. […] By contrast, a gene-editing therapy like the one Zylka developed could be a one-and-done shot, and if administered prenatally or early enough in childhood, a patient and their family would be able to reap the greatest therapeutic benefits. […] It looks like the benefit is going to be the greatest if you do treatment as early as possible. […] For them, he says, the new CRISPR-Cas9 treatment has the potential to be an incredible source for good. […] I think there’s pretty good evidence that its relatively safe to use it in this way.

• #35 Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA | Nature

  https://www.nature.com/articles/s41586-020-2835-2

  Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by a mutation or deletion of the maternally inherited UBE3A allele. […] Here, as part of a systematic screen, we found that Cas9 can be used to activate (’unsilence’) paternal Ube3a in cultured mouse and human neurons when targeted to Snord115 genes, which are small nucleolar RNAs that are clustered in the 3 region of Ube3a-ATS. A short Cas9 variant and guide RNA that target about 75 Snord115 genes were packaged into an adeno-associated virus and administered to a mouse model of AS during the embryonic and early postnatal stages, when the therapeutic benefit of restoring Ube3a is predicted to be greatest. […] This early treatment unsilenced paternal Ube3a throughout the brain for at least 17 months and rescued anatomical and behavioural phenotypes in AS mice. […] Our study shows that targeted genomic integration of a gene therapy vector can restore the function of paternally inherited UBE3A throughout life, providing a path towards a disease-modifying treatment for a syndromic neurodevelopmental disorder.

• #36 Angelman syndrome: first patient to receive potential therapy in Oxford — Department of Paediatrics

  https://www.paediatrics.ox.ac.uk/news/angelman-syndrome-first-patient-to-receive-potential-therapy-in-oxford

  The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford. […] At this time, there is no approved treatment and individuals are managed with non-specific medication to alleviate symptoms of Angelman syndrome. […] GTX-102, an investigational antisense oligonucleotide being developed by GeneTx Biotherapeutics and Ultragenyx Pharmaceutical Inc., is delivered via intrathecal administration; it is designed to target and inhibit the expression of UBE3A-AS with the aim to unsilence the paternal UBE3A copy. […] We are really excited to have dosed the first study participant with a promising potential treatment. Antisense oligonucleotides, genetic therapies really are the future for many more devastating genetic disorders. […] The road before having a treatment for every child with Angelman syndrome in the UK and in the world is still very long, but this is an important first step.

• #37 Angelman Syndrome Gene Therapy Well Tolerated

  https://www.cgtlive.com/view/angelman-syndrome-gene-therapy-well-tolerated

  The gene therapy GTX-102 has been well-tolerated in the first 4 patients with Angelman syndrome (AS) dosed in the phase 1/2 open-label, multiple-dose, dose-escalating KIK-AS study (NCT04259281) in Canada and the UK. […] Investigators observed promising signs of preliminary efficacy in 3 patients. […] The KIK-AS study is evaluating GTX-102, an intrathecally-administered antisense oligonucleotide designed to inhibit UBE3A-AS expression. […] Reactivation of this paternal allele has been associated with improvements in AS neurological symptoms. […] The dosing protocol across the three regions is designed to provide a broad picture on dose response to inform loading and maintenance regimens as we move to the next phase of development. […] We are working with urgency to begin treating study participants in all three regions over the next several months recognizing that there is no approved therapy available for the Angelman community. […] After titration, patients will receive maintenance doses every 3 months and safety and efficacy will continue to be observed. […] GTX-102 is being developed in a partnership between GeneTx and Ultragenyx, as the companies previously announced in 2019.

• #38 Researchers Identify Potential Treatment for Angelman Syndrome | Newsroom

  https://news.unchealthcare.org/2024/07/researchers-identify-potential-treatment-for-angelman-syndrome/

  Researchers in the lab of Ben Philpot, PhD, the Kenan Distinguished Professor of Cell Biology and Physiology at the UNC School of Medicine and associate director of the UNC Neuroscience Center, have identified a small molecule that could lead to a safe and effective treatment for the neurodevelopmental condition known as Angelman syndrome. […] Ben Philpot, PhD, the Kenan Distinguished Professor of Cell Biology and Physiology at the UNC School of Medicine and associate director of the UNC Neuroscience Center, and his lab have identified a small molecule that could be safe, non-invasively delivered, and capable of turning on the dormant paternally-inherited UBE3A gene copy brain-wide, which would lead to proper protein and cell function, amounting to a kind of gene therapy for individuals with Angelman syndrome.

• #38 Researchers Identify Potential Treatment for Angelman Syndrome | Newsroom

  https://news.unchealthcare.org/2024/07/researchers-identify-potential-treatment-for-angelman-syndrome/

  This small molecule provides an excellent starting point for developing a safe and effective treatment for Angelman syndrome. […] Researchers genetically modified mouse neural cells with a fluorescent protein that glows when the paternal UBE3A gene is turned on. […] (S)-PHA533533, a compound that was previously developed as an anti-tumor agent, caused neurons to express a fluorescent glow that rivaled that induced by topotecan, meaning that its effect was potent enough to successfully turn on paternal UBE3A. […] Additionally, researchers observed that (S)-PHA533533 has excellent bioavailability in the developing brain, meaning it travels to its target with ease and sticks around. […] It means it, or a similar compound, has true potential as a treatment for children. […] However, this gives us a compound that we can work with to create an even better compound that could be moved forward to the clinic.

• #39 Researchers identify molecule as potential treatment for Angelman syndrome

  https://medicalxpress.com/news/2024-07-molecule-potential-treatment-angelman-syndrome.html

  Researchers identify a small molecule that could be safe, non-invasively delivered, and capable of „turning on” the dormant paternally-inherited UBE3A gene copy brain-wide, which would lead to proper protein and cell function, amounting to a kind of gene therapy for individuals with Angelman syndrome. […] This small molecule provides an excellent starting point for developing a safe and effective treatment for Angelman syndrome. […] (S)-PHA533533 shows promise, researchers are still working to identify the precise target inside cells that causes the desired effects of the drug. […] This gives us a compound that we can work with to create an even better compound that could be moved forward to the clinic.

• #40 Researchers identify potential treatment for Angelman syndrome | ScienceDaily

  https://www.sciencedaily.com/releases/2024/07/240708101009.htm

  Researchers have identified a small molecule that could lead to a safe and effective treatment for the neurodevelopmental condition known as Angelman syndrome. […] This small molecule provides an excellent starting point for developing a safe and effective treatment for Angelman syndrome. […] No other small molecule compound has yet to show such promise for Angelman. […] Researchers have theorized that turning on the paternal copy of UBE3A could help treat the condition. […] (S)-PHA533533, a compound that was previously developed as an anti-tumor agent, caused neurons to express a fluorescent glow that rivaled that induced by topotecan, meaning that its effect was potent enough to successfully turn on paternal UBE3A. […] This is notable in that previous genetic therapies for Angelman syndrome have had more limited bioavailability. […] It means it, or a similar compound, has true potential as a treatment for children. […] However, this gives us a compound that we can work with to create an even better compound that could be moved forward to the clinic.

• #41 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20240708/Small-molecule-discovery-offers-hope-for-treatment-of-Angelman-syndrome.aspx

  „We still have a lot of work to do before we could start a clinical trial, but this small molecule provides an excellent starting point for developing a safe and effective treatment for Angelman syndrome.” […] Researchers genetically modified mouse neural cells with a fluorescent protein that glows when the paternal UBE3A gene is turned on. […] (S)-PHA533533, a compound that was previously developed as an anti-tumor agent, caused neurons to express a fluorescent glow that rivaled that induced by topotecan, meaning that its effect was potent enough to successfully turn on paternal UBE3A. […] Additionally, researchers observed that (S)-PHA533533 has excellent bioavailability in the developing brain, meaning it travels to its target with ease and sticks around. […] „However, this gives us a compound that we can work with to create an even better compound that could be moved forward to the clinic.”

• #42 Researchers Identify Potential Treatment for Angelman Syndrome – North Carolina Medical Society

  https://ncmedsoc.org/researchers-identify-potential-treatment-for-angelman-syndrome/

  Angelman syndrome is a rare genetic disorder caused by mutations in the maternally-inherited UBE3A gene and characterized by poor muscle control, limited speech, epilepsy, and intellectual disabilities. Though there isn’t a cure for the condition, new research at the UNC School of Medicine is setting the stage for one. […] Ben Philpot, PhD, the Kenan Distinguished Professor of Cell Biology and Physiology at the UNC School of Medicine and associate director of the UNC Neuroscience Center, and his lab have identified a small molecule that could be safe, non-invasively delivered, and capable of “turning on” the dormant paternally-inherited UBE3A gene copy brain-wide, which would lead to proper protein and cell function, amounting to a kind of gene therapy for individuals with Angelman syndrome. […] “We still have a lot of work to do before we could start a clinical trial, but this small molecule provides an excellent starting point for developing a safe and effective treatment for Angelman syndrome.”

• #43 Developing Targeted Therapeutics in Angelman Syndrome

  https://www.neurologylive.com/view/developing-targeted-therapeutics-angelman-syndrome

  OV101 (gaboxadol) is a highly selective extrasynaptic GABAA receptor agonist which binds to the delta-subunit-containing extrasynaptic GABAA receptors. […] OV101 is a GABAA receptor agonist that may restore deficits in tonic inhibition and address the pathophysiology of AS. […] STARS was the first industry-sponsored Phase 2 trial in AS which demonstrated that OV101 is generally safe, well tolerated, and associated with global improvement in AS symptoms.

• #44 Clinical Trials – Angelman Syndrome Foundation

  https://www.angelman.org/as-research/clinical-trials/

  Clinical trials test the safety and effectiveness of a therapy or drug. […] Below you will find information about active or upcoming clinical trials in Angelman syndrome. […] Sponsor Ionis Pharmaceuticals […] Phase 3 […] Participant Age 2 – 50 years […] Locations US, Australia, Israel, Italy, UK […] Sponsor Ultragenyx […] Phase 3 […] Participant Age 4 – 17 years […] Locations US […] Sponsor Hoffman La Roche […] Phase 1 […] Participant Age 1 – 12 years […] Locations US, Italy, Netherlands, Spain […] Sponsor Neuren Pharmaceuticals […] Phase 2 […] Participant Age 3 – 17 years […] Locations Australia […] Sponsor Roche/Genentech […] Phase 2 […] Participant Age 5 – 17 years, Deletion genotype […] Locations US, Australia, France, Italy, Spain

• #45 Angelman Syndrome Foundation – With you for the journey

  https://www.angelman.org/

  ASF funded research advance our understanding of AS and increase the potential for treatment & therapeutics. […] Amazing things have happened because of the ASF-funded LGIT study from Boston’s MassGeneral Hospital. It was the beginning of a new era for treatments for our children with AS. […] Ultragenyx Pharmaceutical Inc. announced today that the first patient(s) has/have been dosed in the pivotal Phase 3 Aspire study evaluating the efficacy and safety of GTX-102, its investigational antisense oligonucleotide (ASO) for Angelman syndrome. […] Ionis Pharmaceuticals has released information regarding their clinical trial of ION582. The trial will move into Phase 3 and will be called Reveal.

• #46 Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA | Ionis Pharmaceuticals, Inc.

  https://ir.ionis.com/news-releases/news-release-details/ionis-treatment-angelman-syndrome-receives-orphan-drug-and-rare

  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an investigational antisense medicine for the treatment of Angelman syndrome, a rare neurogenetic disorder caused by the loss of function of the maternally inherited Ubiquitin Protein Ligase E3A (UBE3A) gene. ION582 targets UBE3A. […] Currently, there are no disease-modifying treatments for Angelman syndrome. […] „Receiving FDA orphan drug designation for ION582 reflects the important and urgent need for delivering an effective treatment to patients living with Angelman syndrome. Ionis is committed to working closely with regulators, clinical investigators, patients and caregivers to advance this novel treatment and make it available to those who need it,” said C. Frank Bennett, Ph.D., executive vice president, chief scientific officer and franchise leader for neurological programs at Ionis. […] ION582 is being evaluated in a Phase 1/2, open-label, dose-escalation clinical study in up to approximately 44 participants with Angelman syndrome.

• #47 Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA

  https://www.prnewswire.com/news-releases/ionis-treatment-for-angelman-syndrome-receives-orphan-drug-and-rare-pediatric-disease-designations-from-us-fda-301566169.html

  Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an investigational antisense medicine for the treatment of Angelman syndrome, a rare neurogenetic disorder caused by the loss of function of the maternally inherited Ubiquitin Protein Ligase E3A (UBE3A) gene. […] Currently, there are no disease-modifying treatments for Angelman syndrome. […] „Receiving FDA orphan drug designation for ION582 reflects the important and urgent need for delivering an effective treatment to patients living with Angelman syndrome. Ionis is committed to working closely with regulators, clinical investigators, patients and caregivers to advance this novel treatment and make it available to those who need it,” said C. Frank Bennett, Ph.D., executive vice president, chief scientific officer and franchise leader for neurological programs at Ionis. […] ION582 is being evaluated in a Phase 1/2, open-label, dose-escalation clinical study in up to approximately 44 participants with Angelman syndrome.

• #48 What Is Angelman Syndrome

  https://www.webmd.com/children/angelman-syndrome

  Theres no cure for Angelman syndrome, but people with the condition can lead happy, fulfilling lives. Medical treatment to manage some symptoms and complications might be necessary. […] For example, they may need: medication for seizures (anticonvulsants), physical therapy to improve balance, braces to help with walking, speech therapy, communication aids, like sign language or technological devices, behavioral therapy for attention problems, medication for feeding problems and constipation. […] Angelman syndrome can cause many kinds of symptoms, so its important to have a team of doctors who specialize in different areas. Your childs care team might include: pediatricians, neurologists (brain and nervous system doctors), geneticists, speech-language pathologists, occupational and physical therapists, behavioral therapists, gastroenterologists (doctors who specialize in the digestive system), nutritionists.

• #49 Answers for Children With Angelman Syndrome | Cedars-Sinai

  https://www.cedars-sinai.org/blog/answers-for-children-with-angelman-syndrome.html

  „Families need a lot of resilience and support to cope and help their child access the best possible treatments and outcomes.” […] „Its a complex condition that affects different systems, and current treatments are insufficient,” said Ochoa-Lubinoff, who oversees Developmental and Behavioral Pediatrics at Cedars-Sinai Guerin Children’s. […] „Less than 1% of Angelman cases have a visible genetic change on a standard test. However, using a combination of newer genetic tests, we can now find the underlying genetic cause in about 90% of casesdramatically speeding up diagnosis,” said Pedro Sanchez, MD, director of Pediatric Medical Genetics at Cedars-Sinai Guerin Childrens. […] „Its really important to get diagnosed earlier, because we are starting to have treatments,” Ochoa-Lubinoff said.

• #50 Angelman Syndrome Clinics across the U.S. – Angelman Syndrome Foundation

  https://www.angelman.org/angelman-syndrome-clinics-across-the-u-s/

  ASF invests $1.5 million to support 17 Angelman Syndrome Clinics across the U.S. […] The purpose of the ASF’s Angelman Syndrome Clinics is to: Provide a “one-stop-shop” medical and psychosocial resource from birth through adulthood for individuals with AS […] Provide a foundation to support future clinical trials by having established sites with AS experts and patients in place to conduct those trials when they become available […] Provide access to a variety of individuals all specializing in AS: clinical geneticist, neurologist, psychiatrist, psychologist, speech language pathologist, physical/occupational therapist, genetic counselor, social worker, and nutritionist. […] Researchers at UNC Chapel Hill Find New Potential Treatment for AS […] Roche Clinical Trial of Rugonersen in Angelman Syndrome.

• #51 Angelman Syndrome Clinic | Kennedy Krieger Institute

  https://www.kennedykrieger.org/patient-care/centers-and-programs/angelman-syndrome-clinic

  The Angelman Syndrome Clinic at Kennedy Krieger Institute is a comprehensive, interdisciplinary clinical program focused on treating people with a genetically confirmed diagnosis of either Angelman syndrome (AS) or maternal 15q duplication (dup15q) syndrome. […] We provide comprehensive medical evaluations, treatment, clinical care and genetic counseling. Our expertise in these rare disorders, combined with our vast resources, ensure that our patients needs can be met at one location. […] While there are no specific treatments that can reverse the symptoms of AS or dup15q syndrome, there are treatments that can improve patients quality of life. We use evidence-based guidelines and standard-of-care practices to address symptoms such as intractable seizures, movement and balance issues, sleep disturbances, and gastrointestinal difficulties. […] Additionally, the clinic serves patients and their families across the lifespan and offers more than just medical care, putting families in touch with national and local resources and assisting with school support, as needed.

• #52 Angelman syndrome | Better Health Channel

  https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/angelman-syndrome

  There is no cure, but the child can benefit from treatment, including physical therapy, special education and behaviour modification. […] There is no cure for Angelman syndrome, but the child can benefit from a range of treatments for some symptoms including: speech therapy, behaviour modification, communication therapy, occupational therapy, physical therapy, special education, social skills training, anti-epileptic medication.

• #53 Angelman syndrome | healthdirect

  https://www.healthdirect.gov.au/angelman-syndrome

  Angelman syndrome can’t be cured, but there is a range of therapies that can improve your child’s quality of life. […] However, there are a range of therapies that can help improve your child’s quality of life: speech therapy and communications and social skills training, occupational therapy, physical therapy to improve posture, balance and movement, physical supports such as back or leg braces, supportive education, medicines to control seizures, such as antiepileptic medicines, therapy to help behavioural problems such as hyperactive behaviour. […] Special education and therapy programs can help people with Angelman Syndrome to communicate and develop skills for daily life.

• #54 Angelman Syndrome Services, Resources & Support: A Comprehensive Guide | Disability Resources

  https://www.disabilityresources.org/angelman.html

  The Angelman Syndrome Foundation provides a comprehensive suite of resources tailored specifically for families and caregivers. […] The Angelman Syndrome Foundation highlights the use of complementary and alternative treatments, particularly for managing problem behaviors in Angelman Syndrome. […] Currently, there is no cure for Angelman Syndrome. However, ongoing research is exploring gene therapy and other treatments to address the genetic root of the disorder. Supportive therapies, such as physical, occupational, and speech therapy, can help manage symptoms and improve quality of life. […] The Foundation for Angelman Syndrome Therapeutics (FAST) is leading the charge in developing cutting-edge treatments for Angelman Syndrome, including gene therapies and small molecule research.

• #55 What is Angelman Syndrome – Angelman Syndrome Foundation

  https://www.angelman.org/what-is-as/

  It is believed that there is a high chance of finding a cure for Angelman syndrome, due to the fact that scientists know what causes AS and have been able to reverse it in mouse models. […] Individuals with AS will require life-long care, but can live long, happy lives.

• #56 Hope for Angelman Syndrome Cure and Treatment

  https://cureangelman.org/hope-for-a-cure

  In AS, the unique nature of the UBE3A gene offers a promising opportunity for potential therapies. […] This presents an exciting possibility: the paternal UBE3A gene could potentially be „turned on” to enable the production of UBE3A protein. […] Traditional strategies used in genetic disorders, such as gene replacement therapy or enzyme replacement therapy, remain potential therapeutic options as well. […] Pillar 1 consists of therapeutic programs that focus on replacing the missing or non-functional maternal copy of the UBE3A gene or protein in neurons of the brain. […] Pillar 2 consists of therapeutic programs that focus on activating the silent copy of the paternal UBE3A gene in the brain. […] Pillar 3 consists of therapeutic programs that focus on different molecular pathways and proteins impacted by the missing UBE3A protein.

• #56 Hope for Angelman Syndrome Cure and Treatment

  https://cureangelman.org/hope-for-a-cure

  Pillar 4 consists of programs and initiatives that focus on work supporting necessary research tools, clinical developments, and community efforts to prepare for AS clinical trials and drug approvals. […] Currently, treatments for AS are generally targeted to the symptoms each individual is experiencing. […] In 2022, a consensus statement on care in AS was published, offering valuable guidance to health care providers about managing symptoms and preventative care for individuals living with Angelman syndrome. […] There is currently no cure for Angelman syndrome. […] However, research is actively progressing, aimed at developing potential therapeutics to improve symptoms and addressing the underlying cause of AS, the missing UBE3A protein in the brain. […] FAST is dedicated to funding innovative research and high-risk, high-reward research aimed at accelerating the development of new therapeutic strategies.

• #56 Hope for Angelman Syndrome Cure and Treatment

  https://cureangelman.org/hope-for-a-cure

  By investing in cutting-edge science, FAST has played a pivotal role in advancing the field to the point where potential meaningful treatments for Angelman syndrome are closer than ever before. […] These efforts not only aim to improve the quality of life for individuals living with Angelman syndrome but also have the potential to positively impact the lives of thousands of individuals worldwide who are affected by similar neurogenetic conditions.

• #57 Angelman Syndrome Treatment Efforts and a Novel Prenatal Strategy – Oligonucleotide Therapeutics Society

  https://www.oligotherapeutics.org/angelman-syndrome-treatment-efforts-and-a-novel-prenatal-strategy/

  Ultragenyx reported in April that its ASO treatment GTX-102, designed to treat Angelman syndrome, was generally safe and led to rapid and clinically meaningful improvements in cognition, communication, and sleep exceeding that of natural history data. […] GTX-102 works by targeting and blocking the expression of the UBE3A-AS gene, which otherwise creates a protein that silences the paternal copy of UBE3A. […] Meanwhile, Ionis – in collaboration with Biogen – is also developing an ASO for Angelman syndrome known as ION582. This drug works like GTX-102 in un-silencing the paternal copy of the UBE3A gene. […] The future of treating Angelman syndrome and other rare conditions […] As 70-80% of these rare disorders are caused by pathogenic genetic alterations in single genes, ASO-based drugs could potentially provide disease-modifying therapies for many of these conditions. […] While delivering an ASO therapy prenatally is still in its early stages, Angelman syndrome is not the first neurodevelopmental disease to show success in preclinical models of in-utero delivery.

• #57 Angelman Syndrome Treatment Efforts and a Novel Prenatal Strategy – Oligonucleotide Therapeutics Society

  https://www.oligotherapeutics.org/angelman-syndrome-treatment-efforts-and-a-novel-prenatal-strategy/

  Angelman syndrome drugs: Ultragenyx and Ionis competing for successful ASO treatment […] The current treatment focuses on symptom management, using anti-seizure medication and physical therapy, but does not address the root cause of the disease, which severely affects both the patient’s and caregiver’s quality of life. […] Recent research exploring the possibility of halting the disease while the child is still in utero, as well as therapies in clinical phases, also holds the potential to change the course of those with Angelman syndrome. […] Prenatal delivery of an antisense oligonucleotide (ASO) could offer a novel strategy for early treatment of Angelman syndrome […] These findings offer a novel strategy for early treatment of AS using an ASO, with two potential routes of administration in the prenatal window.

• #58 Therapeutic Approaches – Cure Angelman Syndrome

  https://cureangelman.org.uk/therapeutic-approaches/

  CRISPR is a powerful gene-editing tool that consists of two components: an enzyme that can cut DNA or RNA and a guide RNA that can recognize specific sequences of DNA or RNA to cut. For Angelman syndrome, CRISPR aims to find a sequence in the human genome that could permanently stop the RNA molecule from silencing the affected gene. There are currently at least three programs in the pipeline for this approach. […] This method involves providing the missing protein directly to the brain. The protein would be modified to enter neurons and function inside and outside the cells. There is currently one program in the pipeline for this approach. […] Both of these therapies introduce an RNA molecule that targets the RNA responsible for silencing the affected gene, activating the gene in neurons. There are currently three programs in the pipeline for this approach.

• #58 Therapeutic Approaches – Cure Angelman Syndrome

  https://cureangelman.org.uk/therapeutic-approaches/

  Angelman syndrome is a complex genetic disorder that affects the nervous system. In this article, we will explore various therapeutic approaches currently being advanced for the potential treatment of humans living with Angelman syndrome. We will discuss each method in simpler terms to help everyone better understand what each one means for our loved ones living with this condition. […] This approach involves delivering a healthy copy of the affected gene directly into brain cells, called neurons. This allows these neurons to make a protein that is either missing or not functioning properly. The therapy can be delivered through different methods, such as an injection into the spinal fluid, directly into the brain tissue, or through a vein. There are currently at least seven programs in the pipeline for this approach.

• #58 Therapeutic Approaches – Cure Angelman Syndrome

  https://cureangelman.org.uk/therapeutic-approaches/

  This method involves putting the affected gene into a patients blood cells. These cells can be removed from the patient and modified to carry the new gene, then injected back into the patient. The cells travel through the bloodstream, cross the blood-brain barrier, and release the new gene into the brain. There is currently one program in the pipeline for this approach. […] These therapies use a combination of synthetic RNA and DNA to bind to a specific RNA molecule responsible for silencing the affected gene in neurons, called UBE3A antisense transcript or UBE3A-ATS. These drugs are designed to unsilence the gene, allowing it to function properly. There are currently at least four programs taking this approach. […] This method involves binding the RNA molecule responsible for silencing the UBE3A antisense transcript in a specific area, resulting in the gene being unsilenced. Research for this approach is ongoing at UC Davis.

• #58 Therapeutic Approaches – Cure Angelman Syndrome

  https://cureangelman.org.uk/therapeutic-approaches/

  This category includes therapies that focus on different molecular pathways and proteins impacted by the missing protein. These drugs generally aim to improve communication between neurons. There are currently at least five different drug candidates in the pipeline for this approach. […] In conclusion, there are at least eight different approaches, including 25 programs, being evaluated to potentially treat Angelman syndrome. This gives us hope for a brighter future for all individuals living with this condition. As research continues, we can expect to see more advancements and promising developments in the treatment of Angelman syndrome. […] Various drug administration methods are being explored for the delivery of potential Angelman syndrome treatments, as each therapeutic approach may require a different route of delivery to ensure its effectiveness.

• #58 Therapeutic Approaches – Cure Angelman Syndrome

  https://cureangelman.org.uk/therapeutic-approaches/

  They are proud to provide funding for a diverse range of therapeutic approaches, reflecting their commitment to explore every possible avenue to help individuals living with this condition. […] FAST has financially supported 16 out of the 25 programs that are currently in the pipeline for Angelman syndrome treatment. This support has been crucial in de-risking these programs and accelerating their progress toward human clinical trials. […] Among these programs, FAST has funded research on Adeno-associated virus gene replacement therapy (AAV-GT) 4 programs, Hematopoietic Progenitor Cell gene replacement therapy (HSC-GT) 1 program, antisense oligonucleotides (ASO) 1 program, CRISPR 2 programs, Enzyme Replacement Therapy (ERT) 1 program, RNA Interference 1 program, and 4 programs in the Downstream targets group.

• #59 Bench to bedside, Carolina leads study of Angelman syndrome | UNC-Chapel Hill

  https://www.unc.edu/discover/bench-to-bedside-carolina-leads-study-of-angelman-syndrome/

  Zylkas lab has been working with CRISPR-Cas9 genome editing technology to reactivate the paternal gene, which worked in a mouse model. […] Because Angelman syndrome is so tied to brain development, early treatment would be critical. […] All kinds of therapy would be involved. But if you do this early enough in life, you should be able to provide a huge benefit, Philpot said. […] Carolina is currently enrolling two of the three gene reactivation trials. […] Its an incredibly educated, motivated community that wants to participate in clinical research, Jalazo said. Theres never been a more hopeful time to have a child diagnosed with Angelman syndrome.

• #59 Bench to bedside, Carolina leads study of Angelman syndrome | UNC-Chapel Hill

  https://www.unc.edu/discover/bench-to-bedside-carolina-leads-study-of-angelman-syndrome/

  Researchers concentrate on the rare disorder not only because they want to help the 500,000 people who have Angelman but also because they think the one defective gene that causes its symptoms could hold the key to other genetic mutations. […] Theres a lot of attention on Angelman syndrome right now. Its poised to be one of the first neurodevelopmental disorders where we have a potentially transformative treatment, Jalazo said. […] Philpots lab is looking at two approaches, one using traditional gene therapy and the other using techniques to reactivate a dormant gene. The gene therapy approach uses a virus to replace the defective gene with a healthy one. […] The reactivation approach is more particular to Angelman syndrome. […] Using a virus, DNA fragments, or a drug has already been shown to work in mice, suggesting that reactivation of paternal UBE3A can be done.

• #60 Angelman Syndrome: New In Utero Candidate Therapy Revealed – BioTechniques

  https://www.biotechniques.com/molecular-biology/angelman-syndrome-novel-in-utero-therapeutic-candidate-promotes-less-invasive-amniotic-delivery/

  A recent mouse model study reveals that a novel in utero treatment for Angelman syndrome delivered through amniotic fluid is as effective as delivery via cerebrospinal fluid. […] Current treatments focus on the management of symptoms, using treatments such as anti-seizure medication and physical therapy, without addressing the root cause of the disease. […] A prenatal approach could help prevent the onset of irreversible organ damage and enable access to neurons during a period when the blood-brain barrier is more permeable. […] Both types of prenatal injections we tried, into the cerebrospinal fluid (IC injection) and the amniotic fluid (IA injection), allowed the therapy to penetrate deep regions of the brain that are critical areas to treat for Angelman Syndrome, said Maria Clark (UCSF), first author of the study. This is a big hurdle to overcome when treating genetic conditions of the nervous system.

• #61 Home – Cure Angelman Syndrome

  https://cureangelman.org.uk/

  At FAST UK, we’re dedicated to keeping our community informed about advancements in Angelman syndrome treatments. […] We’ve provided a link to the global FAST site, where you can explore an up to date overview of the drug development pipeline. […] This resource highlights the progress of various programs, some of which are supported by FAST and others disclosed by external organisations. […] Click below to gain insight into the promising developments bringing us closer to effective treatments and, ultimately, a cure. […] FAST Launches Two Biotech Companies to Advance Investigational Gene-Targeted Therapies for Angelman Syndrome […] Phase 3 Aspire trial of gene therapy GTX-102 doses 1st patient. […] There are many disorders that will not be cured or treated in our lifetime, but Angelman Syndrome will not be one of them.

Zobacz więcej